Clinical Trials
25
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
- Conditions
- Breast CancerProstate CancerAdvanced or Metastatic Solid TumorsRecurrent Ovarian Cancer
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 6
- Registration Number
- NCT06257758
- Locations
- 🇺🇸
Florida Cancer Specialists & Research Institute, Lake Mary, Florida, United States
🇺🇸Stephenson Cancer Center - University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸Next Oncology, San Antonio, Texas, United States
Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors
- Conditions
- Metastatic Castration-resistant Prostate CancerRecurrent Epithelial Ovarian CancerBreast Cancer
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 115
- Registration Number
- NCT05700669
- Locations
- 🇺🇸
Next Oncology, San Antonio, Texas, United States
AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 33
- Registration Number
- NCT03579628
- Locations
- 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇧🇪Grand Hôpital de Charleroi, Charleroi, Belgium
🇫🇷Centre Leon Berard, Lyon, France
Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2016-04-18
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT02548806
- Locations
- 🇬🇧
Simbec Research Limited, Merthyr Tydfil, United Kingdom
Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma
- Conditions
- Melanoma
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2015-09-11
- Lead Sponsor
- Valerio Therapeutics
- Registration Number
- NCT01764009
- Locations
- 🇫🇷
Gustave Roussy Institute,, Kremlin Bicetre, France
🇫🇷Hôpital Saint Louis. Service de dermatologie, Paris, France
🇫🇷CHU Nancy Hôpital Brabois, Vandoeuvre Les Nancy, France
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Valerio Therapeutics Halts Clinical Trials, Pivots to Early-Stage Drug Development
Valerio Therapeutics announces immediate discontinuation of all clinical trials, including the VIO-01 trial, amid financial challenges with only three months of cash runway remaining.
Valerio Therapeutics Expands Antibody Development Capabilities with Emglev Therapeutics Acquisition
Valerio Therapeutics has acquired Emglev Therapeutics, gaining access to innovative single-domain antibody (sdAb) technology that enables fully human antibody development through in vitro processes.